Compare OCS & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCS | ATEC |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | Switzerland | United States |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2006 |
| Metric | OCS | ATEC |
|---|---|---|
| Price | $31.28 | $7.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $42.00 | $22.00 |
| AVG Volume (30 Days) | 432.7K | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $101,739,000.00 |
| Revenue This Year | $466.06 | $18.97 |
| Revenue Next Year | $479.73 | $16.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.00 | $6.82 |
| 52 Week High | $34.48 | $23.29 |
| Indicator | OCS | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 35.69 |
| Support Level | $19.05 | N/A |
| Resistance Level | N/A | $16.22 |
| Average True Range (ATR) | 1.49 | 0.71 |
| MACD | 0.41 | -0.20 |
| Stochastic Oscillator | 62.93 | 17.07 |
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.